Increased Risk of Tourette Syndrome with Leukotriene Modifier Use in Children with Allergic Diseases and Asthma: A Nationwide Population-Based Study

(1) Background: Cysteinyl leukotriene receptor antagonists (LTRAs), including montelukast and zafirlukast, are FDA-approved for treating pediatric asthma and allergic diseases. Tourette syndrome (TS), a common neuropsychiatric disorder in children, is associated with allergic diseases and asthma. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Min-Lan, Lin, Hsiu-Chen, Yen, Chiung-Hui, Ku, Jung-Tzu, Sung, Shian-Ying, Chang, Hsi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688072/
https://www.ncbi.nlm.nih.gov/pubmed/36360335
http://dx.doi.org/10.3390/children9111607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688072/
https://www.ncbi.nlm.nih.gov/pubmed/36360335
http://dx.doi.org/10.3390/children9111607

Ejemplares similares